NDAINTRAVENOUSSOLUTION
Approved
Jun 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
CYCLOPHOSPHAMIDE (cyclophosphamide injection, solution) by Baxter is characterized. Approved for lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma and 4 more indications. First approved in 2023.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cyclophosphamide is an intravenous alkylating agent used to treat hematologic malignancies including lymphomas, myeloma, and leukemia. It works by cross-linking tumor cell DNA and interfering with rapidly proliferating malignant cell growth. The drug was approved in June 2023 and is currently in growth lifecycle stage.
Growth
Product is early in growth phase post-approval, suggesting expanding commercial teams and investment in market development.
Mechanism of Action
characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cyclophosphamide interfere with the growth of susceptible rapidly proliferating malignant cells.
Worked on CYCLOPHOSPHAMIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.